Aspirin's effects on platelet function in patients with immune thrombocytopenia and cardiovascular disease
ASPirin in Immune thRombocytopenia Patients With Cardiovascular disEase
This study tests how low-dose aspirin affects blood platelets in adults with immune thrombocytopenia and heart disease to see if it can help reduce the risk of blood clots.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 1 site (Toulouse) |
| Trial ID | NCT04912505 on ClinicalTrials.gov |
What this trial studies
This study investigates the pharmacodynamics of low-dose aspirin in adult patients with immune thrombocytopenia who are at risk for arterial thrombosis. It aims to assess how daily aspirin intake affects platelet function, particularly in patients with a high turnover of platelets. The study will measure residual platelet function after aspirin intake and explore the relationship between aspirin dosage and arterial thrombosis risk. By understanding these dynamics, the study seeks to optimize aspirin use in this vulnerable population.
Who should consider this trial
Good fit: Ideal candidates include adults with immune thrombocytopenia who are either untreated or on stable treatment and are taking aspirin for cardiovascular disease.
Not a fit: Patients who are currently on other antiplatelet drugs or anticoagulants, or those who are pregnant or breastfeeding, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved aspirin dosing strategies that better protect patients with immune thrombocytopenia from arterial thrombosis.
How similar studies have performed: While studies have shown the importance of aspirin dosing in similar conditions, this specific approach in immune thrombocytopenia is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * adult patients * non-treated immune thrombocytopenia or immune thrombocytopenia with stable treatment (at least 1 month) * treated with aspirin daily for a cardiovascular disease; stable platelet count \< 100 x 109/L * at least one month following an arterial thrombosis * no other antiplatelet drug and anticoagulant * female patient with childbearing potential must have acceptable method of birth control * affiliated or benefiting from public health insurance Exclusion Criteria: * opposition to participate * adults under guardianship or other legal protection * deprived of their liberty by judicial or administrative decision * pregnancy or breastfeeding
Where this trial is running
Toulouse
- Toulouse Hospital — Toulouse, France (Recruiting)
Study contacts
- Principal investigator: Guillaume MOULIS, MD PhD — University Hospital, Toulouse
- Study coordinator: Guillaume MOULIS, MD PhD
- Email: moulis.g@chu-toulouse.fr
- Phone: 05 61 77 58 94
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.